Ibuprofen: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 68: | Line 68: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Latest revision as of 21:55, 20 March 2026
General
- Type: NSAID
- Dosage Forms: Tablets: 100, 200, 400, 600, 800 mg. Suspension: 20mg/ml, 40 mg/ml
- Common Trade Names: Advil; Motrin
Adult Dosing
- 800mg PO Q8hours
- 400mg has been shown to be as effective at pain reduction as 600mg and 800mg[1]
Pediatric Dosing
- 10mg/kg PO Q6hours
- Max: 40mg/kg/day
Special Populations
- Pregnancy Rating: C (1st-2nd trimester), D (3rd trimester)
- Lactation risk categories: L4; enters breast milk, decreases milk supply
- Renal Dosing
- Adult: no adjustment
- Pediatric: no adjustment
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Cardiovascular
- May cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal
- Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery
- Gastrointestinal risk
- Increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal
- Elderly patients are at greater risk for serious GI events.
- Increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal
Adverse Reactions
Serious
- Anaphylaxis
- GI bleeding
- Peptic ulcer disease, gastric perforation, bowel perforation
- Thromboycytopenia
- Agranulocytosis
- Steven-Johnson Syndrome
- Nephrotoxicity
Common
- Dyspepsia
- Nausea
- Abdominal pain
- Constipation
- Headache
- Dizziness
- Rash
- Fluid retention
- Ecchymosis
Pharmacology
- Half-life: 1.8 - 2 hr
- Metabolism: liver
- Excretion: Urine
- Mechanism of Action: exact mechanism unknown; inhibits cyclooxygenase, reducing prostaglandin and thromboxane synthesis
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Acute pain management | 400-800 mg PO q6-8h PRN | Step 1 - Mild pain (NSAID) | PO | Adult |
| Dressler's syndrome | 600-800mg PO q6-8h, taper by 400-800mg/week over 3-4 weeks | NSAID, first-line alternative | PO | Adult |
| Gout and pseudogout | 800mg TID x 3-5 days | First-line NSAID option for acute gout | PO | Adult |
| Pericarditis | 600 mg q8hr x7-10 days, then taper over 3-4 weeks | 1st line anti-inflammatory (alternative) | PO | Adult |
| Urolithiasis | 600mg Q6hrs PRN | Analgesic if tolerating PO | PO | Adult |
See Also
References
- ↑ Motov S, Masoudi A, Drapkin J, et al. Comparison of Oral Ibuprofen at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2019;74(4):530-537. doi:10.1016/j.annemergmed.2019.05.037